The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Naxitamab (NAX) treatment for refractory/relapsed (R/R) high-risk neuroblastoma (HR-NB): Response data and efficacy in patient (pt) subgroups.
 
Jaume Mora
Consulting or Advisory Role - Bristol-Meyers-Squibb/Statistical Horizons; Y-mAbs Therapeutics
Research Funding - Roche/Genentech (Inst)
 
Godfrey Chi-Fung Chan
Leadership - Pangenia; Xellera Therapeutics
Consulting or Advisory Role - Pangenia; Xellera Therapeutics
Speakers' Bureau - Pangenia; Xellera Therapeutics
Patents, Royalties, Other Intellectual Property - Pangenia; Xellera Therapeutics
 
Daniel A. Morgenstern
Honoraria - Ology Medical Education; PlatformQ Health; WebMD
Consulting or Advisory Role - Clarity Pharmaceuticals; EUSA Pharma; Ymabs Therapeutics Inc
Speakers' Bureau - Ymabs Therapeutics Inc
Research Funding - Abbvie (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Cellectar (Inst); Lilly (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Lilly
 
Karsten Nysom
Honoraria - Y-mAbs Therapeutics
Consulting or Advisory Role - Bayer; EUSA Pharma; Ymabs Therapeutics Inc
Travel, Accommodations, Expenses - Bayer
 
Melissa Bear
No Relationships to Disclose
 
Karen Tornøe
Employment - Y-mAbs Therapeutics
Stock and Other Ownership Interests - Y-mAbs Therapeutics
 
Per Settergren Sørensen
Employment - Y-mAbs Therapeutics
Stock and Other Ownership Interests - Y-mAbs Therapeutics
 
Brian H. Kushner
No Relationships to Disclose